Skip to content

Role of Ginger in patients of Osteoarthritis

TO STUDY THE EFFICACY AND TOLERABILITY OF GINGER IN PATIENTS OF OSTEOARTHRITIS OF KNEE - GOA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/10/002082
Enrollment
60
Registered
2011-10-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- OSTEOARTHRITIS KNEE

Interventions

Intervention1: Ginger: Ginger Capsule 750 mg Twice a day orally for 12 weeks Control Intervention1: Diclofenac: Tab Diclofenac 50 mg Twice a day For 12 weeks

Sponsors

SGRDIMSAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of both sexes with symptomatic osteoarthritis of knee who fulfill American college of Rheumatology Criterion for diagnosis of Osteoarthritis 2 Patients having symptomatic Osteoarthritis of knee having knee pain between 40mm and 90 mm on a 100 mm visual analogue scale

Exclusion criteria

Exclusion criteria: 1 Patients with cardiovascular disorders, hypertension and cardiac arrhythmias 2 Pregnant females or those who are planning their pregnancy during the study 3 Patients who have received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last four weeks before reporting to OPD 4 Patients diagnosed to have any inflammatory arthritis gout or acute trauma of knee hip or spine 5 Female patients on oral contraceptives 6 Patients with any known hypersensitivity or contraindication to the drugs in study 7 Patients who present with active concomitant gastroduodenal disorders hepatic and renal impairment 8 Patients with any serious/terminal illness 9 Patients with bleeding disorders 10 Patients with diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Western Ontario and Macmaster Universities Osteoarthrtitis Index. Visual Analogue Scale Timepoint: O WEEK, 2 WEEK, 4 WEEK, 6 WEEK, 8 WEEK, 10 WEEK, 12 WEEK

Secondary

MeasureTime frame
Adverse EventsTimepoint: 0 WEEK ,2 WEEK , 4 WEEK , 6 WEEK, 8 WEEK , 10 WEEK , 12 WEEK

Countries

India

Contacts

Public ContactDr Paramdeep Singh Gill
drnarinder68@gmail.com8427888833

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026